Hepatitis Monthly
Official Journal of Research Center for Gastroenterology and Liver Diseases
Scopus by Title (Ref)
1. Strategies for extending the half-life of biotherapeutics: successes and complications
- Binder U. , et al.
2. A Synopsis of Hepatitis C Virus Treatments and Future Perspectives
- Medina C. , et al.
3. Efficacy and tolerability of peginterferon alpha-2a and peginterferon alpha-2b in Iranian patients with chronic hepatitis C
- Pouresmaeeli M. , et al.
4. Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C
- Hauser G. , et al.
5. Statin efficacy in the treatment of hepatitis C genotype I
- Shavakhi A. , et al.
6. Mysterious linkages between hepatitis C virus genotypes, interleukin-28B genotypes and viral clearance- a meta-analysis
- Aalaei-Andabili S.H. , et al.
7. Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil
- Barros F.M.R. , et al.
8. Incidence and predictors of hematological side effects in chronic HCV Egyptian patients treated with PEGylated interferon and ribavirin
- Lashin A.H. , et al.
9. Cost-effectiveness analysis of adding low dose ribavirin to peginterferon alfa-2a for treatment of chronic hepatitis C infected thalassemia major patients in Iran
- Mehrazmay A. , et al.
12. The effect of peginterferon alpha-2a vs. peginterferon alpha-2b in treatment of naive chronic HCV genotype-4 patients: A single centre egyptian study
- El Raziky M. , et al.
13. Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: An indirect comparison meta-analysis
- Cooper C.L. , et al.
14. Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: A meta-analysis
- Druyts E. , et al.
15. Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis c and pretreatment low platelet counts
- Lin K.H. , et al.
16. High rate of virological response to peginterferon α-2a-ribavirin among non-cirrhotic Iranian hemophilia patients with chronic hepatitis C
- Moghaddam M.A. , et al.
17. Herbal medicine and liver disease, for any conclusion we need to do more studies
- Alavian S. , et al.
18. Proceed with caution: Peginterferon alpha-2a versus peginterferon alfa-2b in chronic hepatitis C. A systematic review of randomized trials
- Kershenobich D. , et al.
19. Peginterferon α-2a and ribavirin treatment of patientswith haemophilia and hepatitis C virus infection: A single-centre study of 367 cases
- Alavian S.M. , et al.
20. Type of pegylated interferon matters: Another milestone in the treatment of hepatitis C virus infection
- Singal A.K. , et al.
21. Which is the IDEAL peginterferon for hepatitis C: A meta-analysis of both pegylated interferons in the treatment of hcv-infected patients
- Tacke F. , et al.
22. Interferon-based therapy for chronic hepatitis C: Current and future perspectives
- de Re V. , et al.
23. Interferon: A sharp sword to overcome HCV or HBV-related liver diseases?
- Jia W.D. , et al.
24. Peginterferon Alpha-2a versus Alpha-2b in chronic hepatitis C
- Kim S.R. , et al.